Published in Annu Rev Pharmacol Toxicol on January 01, 1976
Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature (1980) 2.85
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol (1966) 2.29
Impairment of antipyrine clearance in humans by propranolol. Circulation (1978) 2.18
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry (1999) 2.03
Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med (1968) 1.98
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Pharmacokinetics of methotrexate. Clin Pharmacol Ther (1973) 1.55
Relationship between digoxin concentrations in serum and saliva. Clin Pharmacol Ther (1975) 1.38
The effect of spironolactone on antipyrine metabolism in man. Pharmacology (1973) 1.31
Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology (1993) 1.30
Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem Pharmacol (1974) 1.28
Absorption of orally given digoxin preparations. JAMA (1972) 1.27
The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet (1977) 1.25
Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res (1974) 1.22
Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response. J Cell Biol (1974) 1.21
Di-(2-ethylhexyl)phthalate: an industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rat and mice. Life Sci (1976) 1.14
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation (1969) 1.11
Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms. J Pharm Sci (1978) 1.09
Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res (1979) 1.09
Drugs and drug metabolites as environmental contaminants: chlorophenoxyisobutyrate and salicyclic acid in sewage water effluent. Life Sci (1977) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med (1972) 1.04
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res (1979) 1.00
The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology (1972) 1.00
Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther (1978) 0.99
Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet (1978) 0.99
Prescription writing by generic name and drug cost. J Chronic Dis (1967) 0.96
Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse. Arch Int Pharmacodyn Ther (1977) 0.95
Drug interactions with warfarin. Arch Intern Med (1968) 0.95
A comparative study of drug metabolism in the isolated perfused liver and in vivo in rats. Eur J Pharmacol (1970) 0.95
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Drug interactions. Pharmacol Physicians (1970) 0.93
Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect. Arch Int Pharmacodyn Ther (1969) 0.93
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res (1974) 0.92
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
The effect of spironolactone and canrenone on the digoxin radioimmunoassay. Res Commun Chem Pathol Pharmacol (1974) 0.88
Daunorubicin metabolism in acute nonlymphocytic leukemia. Clin Pharmacol Ther (1973) 0.88
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates. Clin Pharmacokinet (1983) 0.87
The effect of butoxamine on catecholamine-induced metabolic changes in humans. Clin Pharmacol Ther (1966) 0.87
Absorption and excretion of clindamycin-2-phosphate in children after intramuscular injection. Clin Pharmacol Ther (1972) 0.86
Clofibrate effect on catecholamine-induced metabolic changes in humans. Metabolism (1968) 0.86
The instability of isoniazid and acetylisoniazid in frozen plasma. Res Commun Chem Pathol Pharmacol (1976) 0.86
Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643. Arch Int Pharmacodyn Ther (1978) 0.85
Association between clinical cardiac status, laboratory parameters, and digoxin usage. Am Heart J (1976) 0.85
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Absorption of digoxin from different oral preparations in normal subjects during steady state. Clin Pharmacol Ther (1974) 0.85
Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline. Am Rev Respir Dis (1977) 0.84
Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharm Drug Dispos (1981) 0.84
Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets. J Pharm Sci (1974) 0.83
Diphenylhydantoin potency and plasma protein binding. J Pharmacol Exp Ther (1975) 0.83
Effects of selected hypolipidemic drugs on cell ultrastructure. Fed Proc (1971) 0.83
1-methyl-4piperidyl-bis (P-chlorophenoxy) acetate: a new hypolipidemic peroxisome proliferator. Res Commun Chem Pathol Pharmacol (1975) 0.82
Metabolic disposition of antipyrine in patients with lung cancer. Cancer Res (1977) 0.82
Quantitation of lidocaine and its deethylated metabolites in plasma and urine by gas chromatography-mass fragmentography. J Chromatogr (1978) 0.81
Topical application of lindane cream (Kwell) and antipyrine metabolism. J Invest Dermatol (1980) 0.81
Metabolic responses to plasma concentrations of theophylline. Clin Pharmacol Ther (1979) 0.81
Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81
Pharmacology of hypolipidemic drugs. Introduction. Fed Proc (1971) 0.81
Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clin Pharmacol Ther (1978) 0.81
Pharmacokinetic investigations in elderly patients. Clinical and ethical considerations. Clin Pharmacokinet (1990) 0.80
A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci (1977) 0.80
The interaction between halofenate and propranolol. Clin Pharmacol Ther (1976) 0.80
Comparison of charcoal and attapulgite as gastrointestinal sequestrants in acute drug ingestions. Clin Toxicol (1971) 0.80
Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther (1978) 0.79
Species differences in the plasma protein binding of desipramine. J Pharm Pharmacol (1968) 0.79
Serum digitoxin in uremic patients. Clin Pharmacol Ther (1972) 0.79
Daunorubicin metabolism in acute myelocytic leukemia. Blood (1972) 0.79
The effect of DDD on barbiturate and steroid-induced hypnosis in the dog and rat. Biochem Pharmacol (1966) 0.79
A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res (1997) 0.78
Serum quinidine concentrations: comparison of fluorescence, gas-chromatographic, and gas-chromatographic/mass-spectrometric methods. Clin Chem (1976) 0.78
Hepatic catalase is not essential for the hypolipidemic action of peroxisome proliferators. Proc Soc Exp Biol Med (1977) 0.78
The alteration of plasma proteins in uremia as reflected in the ability to bind diphenylhydantoin. Ann N Y Acad Sci (1973) 0.78
Placental transfer and fetal urinary excretion of gentamicin during constant rate maternal infusion. Pediatr Res (1975) 0.78
Bioavailability of aminosalicylic acid and its various salts in humans IV: comparison of four brands of the sodium salt. J Pharm Sci (1974) 0.78
Inhibition of amphetamine tolerance and metabolism by propranolol. J Pharmacol Exp Ther (1974) 0.77
Clinical pharmacokinetics of disopyramide. J Pharmacokinet Biopharm (1982) 0.76
Bioavailability studies on p-aminosalicylic acid and its various salts in man. II. Comparison of parasal and pascorbic. Am Rev Respir Dis (1973) 0.76
Digoxin in hyperthyroidism. Clin Pharmacol Ther (1977) 0.76
One-year trials with halofenate, clofibrate, and placebo. Clin Pharmacol Ther (1976) 0.76
Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype. J Pharmacokinet Biopharm (1980) 0.75
Daunorubicin metabolism: estimation of daunorubicin reductase. Br J Pharmacol (1971) 0.75
In vitro inhibition of rat liver cholest-5en-3 beta-ol (cholesterol) biosynthesis by non-mercurial sulfhydryl reagents. Steroids (1976) 0.75